Stigmatization related to cutaneous neurofibromas in neurofibromatosis 1: development, validation and severity strata of the cNF-PUSH-D
British Journal of Dermatology · 2025
DOI: 10.1093/bjd/ljaf479 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Laura Fertitta und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, National Referral Center for Neurofibromatoses (CERENEF), Henri-Mondor Hospital, Assistance Publique - Hôpitaux de Paris (…. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Skin Neoplasms, Social Stigma, Neurofibroma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Abstract (Originalsprache)
Background
Cutaneous neurofibromas (cNFs) are benign skin tumours affecting over 95% of individuals with neurofibromatosis type 1 (NF1). Their visible appearance often leads to altered body image, social isolation and discrimination. Although stigma is a well-recognized burden in NF1 and has been identified by the Response Evaluation in Neurofibromatosis and Schwannomatosis consortium as a key outcome subdomain for future cNF clinical trials, no specific tool has been developed to assess stigma in relation to cNFs.
Objectives
To adapt, develop and validate a patient-reported outcome measure (PROM) specifically designed to assess stigma in adults with NF1 and cNFs, and to define its severity strata.
Methods
An expert working group including patients with NF1 modified the existing Patient Unique Stigmatization Holistic tool in Dermatology (PUSH-D) (used in chronic dermatoses) to create the 19-item cNF-PUSH-D. Following a pilot phase, a 13-item version was tested and validated through two cross-sectional studies: one in France (n = 224) via the ComPaRe NF1 cohort, and another in the USA (n = 142) via the NF Genetics Cohort. Psychometric properties were evaluated through exploratory and confirmatory factor analyses, Cronbach’s α and intraclass correlation coefficients (ICCs). Convergent validity was assessed against the cNF-Skindex, the Generalized Anxiety Disorder (GAD-7) and the nine-item Patient Health Questionnaire (PHQ-9). Severity strata were defined using responses to a stigma anchor item.
Results
The cNF-PUSH-D demonstrated excellent reliability (Cronbach’s α = 0.941, ICC = 0.939) and strong construct validity. We identified two dimensions: ‘felt stigma’ and ‘enacted stigma’. The score correlated significantly with anxiety, depression and quality-of-life measures (all P < 0.001). Severity strata were defined as low (0–21), moderate (22–32) and high (> 33) stigma (κ = 0.516). A higher number of cNFs (≥ 100) was significantly associated with greater stigma. Scores were comparable between the US and French cohorts, and measurement invariance testing confirmed that the factorial structure remained consistent across countries.
Conclusions
The cNF-PUSH-D is the first validated PROM to assess stigma specific to cNFs. It demonstrates strong psychometric properties across international populations and fills a critical gap for ongoing and future clinical trials in NF1. By quantifying stigma, the tool enables better understanding, monitoring and management of this key aspect of the cNF disease burden. An author video to accompany this article is available online.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Dermatology, National Referral Center for Neurofibromatoses (CERENEF), Henri-Mondor Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), 94010 Créteil, France.
- INSERM, Centre d'Investigation Clinique 1430, National Referral Center for Neurofibromatoses (CERENEF), Henri-Mondor Hospital, Assistance Publique-Hôpitaux Paris (AP-HP), 94010 Créteil, France.
- INSERM U955, IMRB, 94010, Créteil, France.
- Department of Dermatology, Stanford Medicine, Stanford University, Redwood City, CA, USA.
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Center for Clinical Epidemiology, Hôtel-Dieu Hospital (AP-HP), Paris, France.
ORCID-Profile: Laura Fertitta, Jaishri O Blakeley, Viet-Thi Tran
Zitieren
APA
Fertitta, L., Sarin, K. Y., Romo, C. G., Bergqvist, C., Blakeley, J. O., Peiffer, B., Tran, V. T., Armand, M. L., Moryousef, S., Ferkal, S., Le Corvoisier, P., Ezzedine, K., & Wolkenstein, P. (2025). Stigmatization related to cutaneous neurofibromas in neurofibromatosis 1: development, validation and severity strata of the cNF-PUSH-D. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljaf479
Vancouver
Fertitta L, Sarin KY, Romo CG, Bergqvist C, Blakeley JO, Peiffer B, et al. Stigmatization related to cutaneous neurofibromas in neurofibromatosis 1: development, validation and severity strata of the cNF-PUSH-D. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljaf479
BibTeX
@article{Fertitta2025,
author = {Fertitta, Laura and Sarin, Kavita Y and Romo, Carlos G and Bergqvist, Christina and Blakeley, Jaishri O and Peiffer, Bastien and Tran, Viet-Thi and Armand, Marie-Laure and Moryousef, Sabine and Ferkal, Salah and Le Corvoisier, Philippe and Ezzedine, Khaled and Wolkenstein, Pierre},
title = {Stigmatization related to cutaneous neurofibromas in neurofibromatosis 1: development, validation and severity strata of the cNF-PUSH-D},
journal = {British Journal of Dermatology},
year = {2025},
doi = {10.1093/bjd/ljaf479}
}
EUVIMED